KLRK1 and Miyoshi myopathy: A phase I clinical trial on the use of NKG2D CAR-T cells in AML/MDS and MM demonstrated that NKG2D CAR-T cells are safe, with no dose-limiting toxicities, cytokine release syndrome, CAR-T cell-related neurotoxicity, or autoimmune reactions (16).